Farmers & Merchants Investments Inc. Acquires 1,000 Shares of Kenvue Inc. (NYSE:KVUE)

Farmers & Merchants Investments Inc. increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,910 shares of the company’s stock after purchasing an additional 1,000 shares during the quarter. Farmers & Merchants Investments Inc.’s holdings in Kenvue were worth $1,578,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in KVUE. Grove Bank & Trust increased its position in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Kenvue in the fourth quarter valued at $29,000. Riverview Trust Co acquired a new position in Kenvue during the third quarter worth $30,000. Fortitude Family Office LLC raised its position in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in Kenvue in the third quarter valued at $35,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the topic of several recent analyst reports. Bank of America boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Canaccord Genuity Group dropped their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday. Finally, UBS Group reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $23.00.

Kenvue Price Performance

Shares of Kenvue stock opened at $20.23 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $38.79 billion, a price-to-earnings ratio of 38.17, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a 50-day simple moving average of $21.54 and a two-hundred day simple moving average of $21.95.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 4.05%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.